It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
ecDNA is an important driver of aggressive adult cancers, but its role in pediatric tumors is not yet well-understood. To survey the genomic landscape of ecDNA amplifications across pediatric cancers, we applied computational methods to detect ecDNA in the genomes of a cohort of 1670 pediatric tumors from 1481 patients. ecDNA was detected in at least 10% of pediatric ETMR, osteosarcoma, rhabdomyosarcoma, high-grade glioma, retinoblastoma, and medulloblastoma (MB) tumors. To assess the clinical importance of ecDNA in MB, the most common malignant pediatric brain tumor, we applied the same methods to a cohort of 468 MB patients. ecDNA was detected in 18% of MB tumors and carried a threefold greater risk of mortality within 5 years. Affected genomic loci harbor up to hundredfold amplification of oncogenes including MYC, MYCN, TERT, and other novel putative oncogenes. To elucidate the functional regulatory landscapes of ecDNAs in MB, we generated transcriptional (RNAseq), accessible chromatin (ATAC-seq), and chromatin interaction (Hi-C) profiles of 6 MB tumor samples. In each case, we identified regulatory interactions that cross fusion breakpoints on the ecDNA, representing potential “enhancer rewiring” events which may contribute to transcriptional activation of co-amplified oncogenes. To test this hypothesis, we conducted an in vitro CRISPRi screen targeting regulatory regions on the ecDNA of a MB cell line and identified distal enhancers which promote proliferation. Using single-cell sequencing, we have also developed methods to explore intratumoral heterogeneity of ecDNA in a p53-mutant SHH MB patient tumor and its corresponding PDX model. In summary, our study analyzes the frequency, diversity, and functional relevance of ecDNA across MB subgroups and provides strong justification for continued mechanistic studies of ecDNA in MB with the potential to uncover new therapeutic approaches.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer